Disclosed are imidazopyridazinyl compounds of Formula (I): (I), or pharmaceutically salts and prodrugs thereof, wherein R
3
is C
2-4
alkenyl or a cyclic group, and R
1
and R
2
are defined herein. Also disclosed are methods of using such compounds in the treatment of at least one CYP17 associated condition, such as, for example, cancer, and pharmaceutical compositions comprising such compounds.
Disclosed are imidazopyridazinyl compounds of Formula (I): (I), or pharmaceutically salts and prodrugs thereof, wherein R3 is C2-4alkenyl or a cyclic group, and R1 and R2 are defined herein. Also disclosed are methods of using such compounds in the treatment of at least one CYP17 associated condition, such as, for example, cancer, and pharmaceutical compositions comprising such compounds.
IMIDAZOPYRIDAZINYL COMPOUNDS AND THEIR USES FOR CANCER
申请人:Bristol-Myers Squibb Company
公开号:EP2563792B1
公开(公告)日:2014-08-27
US9145419B2
申请人:——
公开号:US9145419B2
公开(公告)日:2015-09-29
[EN] IMIDAZOPYRIDAZINYL COMPOUNDS AND THEIR USES FOR CANCER<br/>[FR] COMPOSÉS D'IMIDAZOPYRIDAZINYLE ET LEURS UTILISATIONS POUR LE CANCER
申请人:BRISTOL MYERS SQUIBB CO
公开号:WO2011137155A1
公开(公告)日:2011-11-03
Disclosed are imidazopyridazinyl compounds of Formula (I): (I), or pharmaceutically salts and prodrugs thereof, wherein R3 is C2-4alkenyl or a cyclic group, and R1 and R2 are defined herein. Also disclosed are methods of using such compounds in the treatment of at least one CYP17 associated condition, such as, for example, cancer, and pharmaceutical compositions comprising such compounds.